



Borders Formulary Committee

Annual Report

April 2018 – March 2019

CONTENTS

1	NHS Borders Formulary Committee Purpose	Page 3
2	BFC Membership	Page 3
3	Business	Page 3
4	BFC – Formulary Updates	Page 4
5	BFC – Applications and Decisions	Page 5-7
6	BFC Meeting Attendees 2018/19	Page 8

1. Purpose

Borders Formulary Committee is a sub committee of the Area Drug and Therapeutics Committee and is accountable to the Strategy Group.

Its purpose is to provide NHS Borders Board with the assurance that mechanisms are in place and effective across NHS Borders to manage requests to support cost-effective, evidence based, prescribing of medicines.

2. BFC Membership

During the financial year ending 31 March 2019, membership of NHS Borders Formulary Committee comprised:

Mrs Alison Wilson (Chair) – Director of Pharmacy

Ms Liz Leitch – Formulary Pharmacist

Mrs Catherine Scott – Senior Clinical and Development Pharmacist

Mr Keith Maclure – Prescribing Support Pharmacist

Dr Paul Neary – Consultant Cardiologist

Dr Joanne Graham – Medical Registrar – left NHS Borders August 2018

Dr Nicola Henderson – GP

Dr Subodh Subodh - Consultant Psychiatrist

Minute Secretary

Kate Warner – PA to Director of Pharmacy

3 Business

Core agenda items on the Committee's agenda include:-

- Committee members review New Medicine Applications for drugs from NHS Borders clinicians to be included in the formulary.
- Committee members note medicines reviewed by the Scottish Medicine Consortium (SMC), and guidance published by NICE, SIGN and NHS Quality Improvement Scotland (QIS).
- Borders Joint Formulary Updates – committee members review and approve changes to formulary sections. The committee supports development of guidelines & protocols relating to safe use of medicines.
- Patient Safety.
- For noting – minutes from Tissue Viability Group, Wound Formulary Group and NHS Lothian Formulary Committee; Single National Formulary updates.

4 BFC – Formulary, Guideline and Protocol Updates

FORMULARY UPDATES BROUGHT TO BFC MEETING – 11th APRIL 2018
Endocrine System and Skin Chapters formulary section updates.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 11th APRIL 2018
In-patient Insulin Use and Supply guidance; Mesalazine Oral Preparations update.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 13th JUNE 2018
Bath additives – Emollients; Edoxaban – second choice NOAC/DOAC; Dovobet formulary update; Abbreviated Borders Joint Formulary update and approval.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 13th JUNE 2018
PACS Tier Two update to national paperwork.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 8th AUGUST 2018
Flash Glucose monitoring strips and Freestyle Libre update.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 8th AUGUST 2018
HRT Guidance and Treatment Pathway flow-chart update.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 10th OCTOBER 2018
Central Nervous System - Mental Health formulary section update; Paravit CF liquid and capsules; Freestyle Libre update; Gluten Free Formulary update.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 10th OCTOBER 2018
Inpatient Influenza Vaccination in DME.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 12th DECEMBER 2018
Edoxaban – second choice, Apixaban – first choice NOAC/DOAC; Central Nervous System – Hypnotics and Anxiolytics formulary section update.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 12th DECEMBER 2018
Guidance for Initiating Anti-Depressant Therapy; Medication Algorithm for Secondary Prevention after TIA/Ischaemic Stroke; Statins guidance.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 13th FEBRUARY 2019
Dalteparin supply issue – Edoxaban; formulary amendment for Empagliflozin and Nefopam.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 13th FEBRUARY 2019
Process for Emergency Unlicensed Medicine/Off-label Non Formulary Requests; group IPTR move to PACS Tier Two process.

5 BFC – Applications and Decisions

New Medicine Product/Device Endorsement Categories

A	Approved for general use - hospital and general practice
B	Approved for specialist use only
C	Approved for specialist initiation, with ongoing prescribing in general practice
D	Approved for shared care between hospital and general practice. Shared care protocol to be developed. (Information included here)
E	Not approved (reason given)
F	No decision – further information required (listed here)

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 11 th APRIL 2018			
NMA	Indication	Speciality	BFC Decision
Dimethyl fumarate (Skilarence)	Treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy	Dermatology	Category B
Sarilumab (Kevzara)	In combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Sarilumab can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. SMC restriction: in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs. In patients with severe disease inadequately controlled by a TNF antagonist, it may be used in patients ineligible to receive rituximab	Rheumatology	Category B
Fomepizole	Ethylene Glycol Poisoning	Emergency Department	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 13 th JUNE 2018			
NMA	Indication	Speciality	BFC Decision
Aerochamber Plus Flow Vu	Spacer device for inhalers.	Respiratory	Category F
Guselkumab (Tremfya)	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.	Dermatology	Category B
Brodalumab (Kyntheum®)	Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. SMC restriction: for patients who have	Dermatology	Category E

	failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra indication to these treatments.		
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 8th AUGUST 2018			
NMA	Indication	Speciality	BFC Decision
Brodalumab (Kyntheum®)	Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra indication to these treatments.	Dermatology	Category B
Aerochamber Plus Flow Vu	Spacer device for inhalers.	Respiratory	Category A
Tacrolimus (Adoport)	Prophylaxis of renal transplant rejection	Renal	Category C
Aripiprazole (Abilify)	Control of agitation and disturbed behaviour in schizophrenia	Mental Health	Category B
Guanfacine (Intuniv)	Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.	Mental Health	Category E Continue to be Non-formulary requests
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 10th OCTOBER 2018			
NMA	Indication	Speciality	BFC Decision
Nalmafene (Selincro)	Reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL) two weeks after initial assessment, without physical withdrawal symptoms and who do not require immediate detoxification in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.	Borders Addiction Service	Category F; Additional information requested.
Olanzapine (Zyprexa IntraMuscular)	Rapid tranquilisation in patients who haloperidol IM is contra-indicated (e.g. QTc prolongation or already prescribed a QT prolonging medication or who have had an acute dystonia with first generation antipsychotics in the past).	Mental Health	AMBER
Cladribine (Mavenclad)	Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.	Neurology	Category B
Dolutegravir 50mg/Rilpivirine 25mg (Juluca)	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor.	Sexual Health	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 12th DECEMBER 2018			
NMA	Indication	Speciality	BFC Decision
Bictegravir / Emtricitabine	Treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or	Sexual Health	Category B

/ Tenofovir alafenamide (Biktarvy)	past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Bictegravir / emtricitabine / tenofovir alafenamide was non-inferior for control of HIV-1 infection compared with anti-retroviral regimens comprising an integrase inhibitor plus backbone of dual nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in treatment-naïve adults. Bictegravir / emtricitabine / tenofovir alafenamide was non-inferior to anti-retroviral regimens containing a dual NRTI backbone plus an integrase inhibitor or a protease inhibitor in maintaining virological suppression in virologically suppressed adults		
Tadalafil (Cialis / generic)	Regular once-daily administration in patients with erectile dysfunction responding to an on-demand regimen of tadalafil who anticipate frequent use (at least twice a weekly)	Urology	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 13th FEBRUARY 2019			
NMA	Indication	Speciality	BFC Decision
Adex Gel	Patients with dry and inflamed skin conditions, such as eczema and psoriasis. Adex Gel is particularly useful in circumstances where the anti-inflammatory action maybe beneficial especially where the condition is not sufficiently controlled using emollients alone, or during flares.	Dermatology	Category B – 6 mth trial with feedback
Thrombin (Flo seal)	Injecting Gastric Varices	Gastroenterology	Category B
Tofacitinib citrate (Xeljanz)	Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.	Gastroenterology	Category B
Estradiol (Oestrogel)	Menopausal symptoms. To be used with cyclical progestogen for at least 12 days of each cycle for women with uterus.	Sexual Health	Category C

6 BFC Meeting Attendees 2018/19

Name	Meeting Dates					
	11.04.18	13.06.18	08.08.18	10.10.18	12.12.18	13.02.19
Mrs Alison Wilson	✓	✓	✓	✓	✓	✓
Ms Liz Leitch	✓	✓	✓	✓	✓	✓
Mrs Catherine Scott	✓	✓	✓	✓	✓	✓
Mr Keith Maclure	✓			✓	✓	
Mr Adrian Mackenzie					✓	
Dr Paul Neary		✓	✓		✓	✓
Dr Joanne Graham	✓					
Dr Nicola Henderson		✓	✓	✓	✓	✓
Dr Subodh Subodh						✓
Kate Warner (Minute)	✓	✓	✓		✓	✓
Fiona Black (Minute)				✓		
Guests						
Mairi Cromarty (Clinical Pharmacist)	✓					
Elaine Hancock (Prescribing Support Pharmacist)			✓			
Katarzyna Nowak (Clinical Pharmacist)			✓			
Aleena Mehan (Pharmacist)				✓		
Paulina Mlawa (Clinical Pharmacist)					✓	
Susan Anderson (Prescribing Support Pharmacist)					✓	

Declarations of Interest

No declarations of interest during 2018/19 meetings.